share_log

普利制药(300630.SZ)收到中国证监会立案告知书

Puli Pharmaceuticals (300630.SZ) received a notice from the China Securities Regulatory Commission to file a case

Zhitong Finance ·  May 8 08:50

Puli Pharmaceuticals (300630.SZ) announced that the company received from the China Securities Regulatory Commission on May 8, 2024...

Zhitong Finance App News, Puli Pharmaceuticals (300630.SZ) announced that the company received the “Notice of Case Filing” from the China Securities Regulatory Commission on May 8, 2024. The China Securities Regulatory Commission decided to file a case against the company on May 8, 2024, according to relevant laws and regulations because the company did not disclose the 2023 annual report within the statutory period and is suspected of violating information disclosure regulations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment